A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

BACKGROUND: The objectives of this phase I study were to assess the safety and tolerability of E7080 in patients with advanced, refractory solid tumours; to determine the maximum tolerated dose (MTD) and pharmacokinetics profile of E7080; and to explore preliminary evidence of its anti-tumour effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Boss, D S, Glen, H, Beijnen, J H, Keesen, M, Morrison, R, Tait, B, Copalu, W, Mazur, A, Wanders, J, O'Brien, J P, Schellens, J H M, Evans, T R J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349182/
https://www.ncbi.nlm.nih.gov/pubmed/22516948
http://dx.doi.org/10.1038/bjc.2012.154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349182/
https://www.ncbi.nlm.nih.gov/pubmed/22516948
http://dx.doi.org/10.1038/bjc.2012.154

Ejemplares similares